No abstract

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disease that leads to dementia and eventual death, the reason why screening is so beneficial in its early stages. Recent evidence suggests that memory and vision impairments are closely linked to Alzheimer’s disease. Moreover, assessing vision disorders may improve early detection and treatment of dementia. Therefore, some research has been conducted on screening for AD disease using new machine learning (ML) techniques on novel ophthalmologic biomarkers data. Objective: To summarize existing findings on machine learning models exploring eye changes data to predict cognitive decline in the context of AD. Methods: Systematic review of original research between January 2016 and August 2021. A search covered two databases on (Scopus) and (PubMed). Results: From 104 search results, 13 articles were selected after using the eligibility criteria: 5 machine learning models used retinal texture data, 5 models included eye movement data, 2 proposed models used iris change data, and 1 proposed model used corneal nerve loss data. Conclusion: Promising results are reported in almost all 13 studies, but very few have been implemented in research or clinical practice. The principal constraints in this area are limited standardization and comparability of results..

BackgroundThe treatment of spondyloarthritis (SpA) is based on cDMARDS (Conventional disease-modifying anti-rheumatic drugs) and bDMARDS (Biologic disease-modifying anti-rheumatic drugs) and aims at remission or low disease activity. Elevated C-reactive protein (CRP) is a good marker of inflammation [1].ObjectivesOur goal was to find a link between the CRP level and the response to infliximab.MethodsRetrospective study was conducted in the rheumatology department at the University Hospital of Fez from January 2011 to January 2021. The patients were recruited according to the ASAS 2009 criteria (Assessment of Spondyloarthritis International Society). A negative CRP is defined as less than or equal to 6mg / L and the ESR (Erythrocyte Sedimentation Rate) according to age. The main criteria for evaluating the response to the biological at 3, 6 and 12 months are: BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASDASCRP (Ankylosing Spondylitis Disease Activity Score). The secondary criteria are: global evaluation (EVA) and ESR. They were divided into 2 groups according to the CRP while seeking its link with the response to infliximab and with the other epidemiological, clinical and biological parameters.Results375 SpA patients including 65 on infliximab: 50.8% men and 49.2% women. Mean age was 43.40(±1.86) years. Average duration of evolution was 7.71(±6.33) years. Mean baseline CRP was 35.1(±42.7) mg/L. Mean baseline ASDASCRP was 4.04(±1.49). 77.4% had a good ASDAS CRP response to treatment and 22.6% had no response. 59.7% had a good answer according to BASDAI. The bivariate analysis did not find a significant relationship between the initial CRP and the main treatment response criteria: ASDASCRP (p=1) BASDAI (p=0.14), nor with ESR (p= 0.09) and overall EVA (p=0.1).ConclusionNo relationship was found between baseline CRP and disease remission. Further studies with a larger sample would be needed to discuss these results.References[1]A. Guich et al, Taux de CRP initial et réponse au traitement biologique de la spondylarthrite, Revue du rhumatisme 87 (2020) A107–A293Disclosure of InterestsNone declared

BackgroundThe use of biological treatment in psoriatic arthritis has revolutionized its management with both joint and skin efficacy [1].ObjectivesThe goal of our study was to evaluate the use of biological treatment in these patients and to assess the factors associated with it.MethodsRetrospective study conducted within the rheumatology department of the University Hospital of Fez. Patients were recruited from January 2011 to January 2021. We included patients with psoriatic arthritis according to CASPAR criteria and assessed the use of biotherapy as well as the epidemiological, clinical and biological factors associated with it.ResultsThere were a total of 98 patients with psoriatic arthritis, 21 of whom had been put on biological treatment. Of the total of 21 patients, there were 42.9% women and 57.1% men, the average age was 51.1 (± 9.92) years. 20% of patients had a history of tuberculosis, 14.3% had diabetes, 10% had hypertension and 30% had dyslipidemia. 60% of patients had an inflammatory syndrome, 73% had radiographic sacroiliitis and 63.2% had functional repercussions. In bivariate analysis, the value of the initial C-reactive protein CRP (p = 0.04), the initial disease activity score DAS 28 CRP (p = 0.0001) and the value of the initial erythrocyte sedimentation rate ESR (p = 0.02) were significantly associated with the use of biotherapy, there was no significant association with the other parameters. In multivariate analysis, no factor was significant.ConclusionAn active psoriatic arthritis predicts the prescription of a biological treatment, other studies with a larger sample would be necessary to confirm our results.References[1]Julien Schemoul et al, Stratégies thérapeutiques dans le rhumatisme psoriasique, Revue du rhumatisme (2017)-4907.Disclosure of InterestsNone declared

No abstract